Podcast appearances and mentions of lambert initiative

When you take a prescription medication, it goes into your body, does what it is supposed to and then leaves. Part of leaving the body often involves the medication getting broken down or metabolized by enzymes in the liver. One of the biggest medication metabolizing enzyme systems in the liver is called the Cytochrome P450 enzymes. Why should you care? Because cannabis can effect the Cytochrome P450 enzymes. That could cause there to be too much or too little of a prescription medication in your body to do its job properly. Dr. Lyndsey Anderson and her colleagues at the Lambert Initiative for Cannabinoid Therapeutics in Sydney, Australia have looked at how cannabis and the Cytochrome P450 enzymes interact. Let's have a listen!Lambert Initiative for Cannabinoid Therapeutics - web siteLyndsey Anderson - LinkedInMusic by:Emre Cords-Before We Decided to Fall -YouTube(Yes we got a SOCAN membership to use this song all legal and proper like)Additional Music:Desiree Dorion desireedorion.comMarc Clement - FacebookTranscripts, papers and so much more at: reefermed.ca

Danielle McCartney is a Postdoctoral Research Associate at the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. Her main role is to coordinate clinical research into the effects of cannabidiol on simulated car driving performance.  Danielle and her colleagues recently published a systematic review of 20 studies that examine the next-day effects of THC. As the study states, “The length of time an individual should wait following cannabis use before performing safety-sensitive tasks, is a critical issue.” Some government agencies and experts recommend individuals avoid performing safety-sensitive tasks for at least 24 hours. It should not surprise you to learn that the data suggests a much shorter impairment window. During our conversation, we discuss: The different types of studies the authors reviewed and the criteria they used to evaluate them The different tests administered to measure impairment How next-day effects of THC compare to acute effects How next-day effects are different in medicinal cannabis patients vs. recreational users What methods are available to determine THC impairment in drivers What is a reasonable impairment window for THC Thank You to This Episode's Sponsor: Medicine Women Health Medicine Women's team of specialists includes Medical Doctors, Naturopaths, Medical Cannabis Experts, Nutritionists and Alternative Health Practitioners. These integrative teams evaluate health issues and design targeted protocols to promote personal healing. Medicine Women's Protocols have successfully alleviated symptoms of Cancer, Auto-Immune Diseases and Neurological Conditions, as well as providing overall Health Rejuvenation. Learn more at www.medicinewomenhealth.com.  Additional Resources The “Next Day” Effects of Cannabis Use: A Systematic Review Determining the magnitude and duration of acute Δ9-tetrahydrocannabinol (Δ9-THC)-induced driving and cognitive impairment: A systematic and meta-analytic review Lambert Initiative for Cannabinoid Therapeutics Review the Podcast! CannMed Archive CannMed Community Board [Facebook Group]

A conversation about cannabinoid science and developments in medical cannabis research with Cilla Zhou from the Lambert Initiative for Cannabinoid Therapeutics.

A conversation about cannabinoid science and developments in medical cannabis research with Cilla Zhou from the Lambert Initiative for Cannabinoid Therapeutics.

On this episode, we are joined by Rhys Cohen. Rhys has delivered consulting projects to most of Australia's leading cannabis companies and is currently the Senior Corporate Communications Manager at Cann Group. He sits on the non-executive advisory board of the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney, and was previously editor-at-large at Cannabiz, Australia's leading B2B industry publication. Topics: 1. Politics & Economics of Cannabis 2. Industry Analysis 3. Overview of Australia * Twitter - @TheCannabisRev2 * LinkedIn - @thecannabisreview * Episode Library - https://www.irishmedianetwork.com/the... + Cann-Group https://www.canngrouplimited.com/

When you take a prescription medication, it goes into your body, does what it is supposed to and then leaves. Part of leaving the body often involves the medication getting broken down or metabolized by enzymes in the liver. One of the biggest medication metabolizing enzyme systems in the liver is called the Cytochrome P450 enzymes. Why should you care? Because cannabis can effect the Cytochrome P450 enzymes. That could cause there to be too much or too little of a prescription medication in your body to do its job properly. Dr. Lyndsey Anderson and her colleagues at the Lambert Initiative for Cannabinoid Therapeutics in Sydney, Australia have looked at how cannabis and the Cytochrome P450 enzymes interact. Let's have a listen!Music by:Emre Cords-Before We Decided to Fall https://www.youtube.com/watch?v=orekXjikSG8(Yes we got a SOCAN membership to use thissong all legal and proper like)Additional Music:Desiree Dorionwww.desireedorion.com/Marc Clementhttp://marcclementmusic.com/

We're joined by Dr Danielle McCartney, an Accredited Sports Dietitian & researcher at The Lambert Initiative for Cannabinoid Therapeutics. Danielle provides a fascinating overview of CBD use for sport. What are the potential uses? Is it safe, legal, how do you buy it, and is the hype justified?

(Part 2) What happens when CB1 Receptors are removed from the body? Or when the enzyme (FAAH) that breaks down your own endocannabinoids is no longer present in the body? Our guest, Iain McGregor, Professor of Psychopharmacology at University of Sydney & Academic Director at the Lambert Initiative for Cannabinoid Therapeutics, discusses new findings and what lies ahead in cannabis research. P.S. World's best search engine for Video Cannabis Education = PeriodicSearch.com Schedule 1-on-1 call w/ Wayne (Office Hours, Fri 2-4pm PST) *read details for 1-on-1 calls in this calendar link Send a Message = Contact Us

(Part 1) Sometimes a single story can do more than mountains of research data. Previous decades only allowed the research of cannabis when looking at it's harm potential, however recent times have changed. Our guest, Iain McGregor, Professor of Psychopharmacology at University of Sydney & Academic Director at the Lambert Initiative for Cannabinoid Therapeutics, discusses new findings and what lies ahead. P.S. World's best search engine for Video Cannabis Education = PeriodicSearch.com Schedule 1-on-1 call w/ Wayne (Office Hours, Fri 2-4pm PST) *read details for 1-on-1 calls in this calendar link Send a Message = Contact Us

This week we're joined by Rhys Cohen, Australian Cannabis Consultant, and Editor at Large of Cannabiz Australia.In this episode, Rhys gives us a high level overview of cannabis down-under, including its changing public perceptions, patient access to medical products, and progress towards decriminalisation. → View full show notes, summary, and access resources here: https://www.canverse.global/shownotes/e110About RhysRhys has delivered consulting projects to most of Australia's leading cannabis companies and has worked extensively with the Lambert Initiative for Cannabinoid Therapeutics at the University of Sydney. He has presented at numerous industry events including ACannabis (2021); Prohibition Partners Live (2020); and New Frontier Global Cannabis Town Hall (2020). His industry analysis has been cited by Deloitte Access Economics; the Victorian Department of Economic Development, Jobs, Transport and Resources; the Commonwealth Office of Drug Control; the Commonwealth Senate Standing Committee on Community Affairs; and the International Journal of Drug Policy. Rhys has also appeared in ABC News; The Australian Financial Review, The Age; The Sydney Morning Herald; and MJBiz Daily. He is the editor-at-large for Australia's leading industry news platform Cannabiz. And he sits on the Advisory Board of market intelligence and research company FreshLeaf Analytics.Quotables‘[In Australia] the existence of the medical properties of cannabis are not disputed by anyone' 06:31Once it becomes easy and cheap enough here is no reason why other people who aren't medicinal cannabis patients could start accepting cannabis on prescription. That combined with the public change in attitudes towards cannabis legalisation more generally… I think we're approaching a point in which we're going to start having the initial conversation about cannabis law reform' 32:00ResourcesJoin Rhys on LinkedIn: https://www.linkedin.com/in/rhyscohen/Rhys's Website: https://www.rhyscohen.com/Join Rhys onTwitter: https://twitter.com/rhyscohenCannabis Australia: https://www.cannabiz.com.au/

Australians regularly rank as some of the happiest people on Earth, but we also are second highest on the list when it comes to taking antidepressants, so why aren't we talking about this? The Quicky investigates how many of us are using medication to help treat our mental health issues, how it works, and what we can do to break down the stigma surrounding this form of treatment. Subscribe to The Quicky at... https://mamamia.com.au/the-quicky/ CREDITS  Host/Producer: Claire Murphy Executive Producer: Siobhán Moran-McFarlane Audio Producer: Jacob Round Guests: Professor Philip Boyce - Professor of Psychiatry at Westmead Hospital, and Head of the Perinatal Psychiatry Clinical Research Unit at Westmead Hospital in Sydney. Dr Izelle Labuschagne - clinical neuroscientist and a Research Fellow in the Cognition and Emotion Research Centre within the School of Psychology at the Australian Catholic University in Melbourne. Professor Iain McGregor - National Health and Medical Research Council Principal Research Fellow, Professor of Psychopharmacology, and Academic Director of the Lambert Initiative for Cannabinoid Therapeutics. Emmeline - Takes antidepressants to treat ongoing anxiety. CONTACT US Got a topic you'd like us to cover? Send us an email at thequicky@mamamia.com.au Mamamia acknowledges the Traditional Owners of the Land we have recorded this podcast on, the Gadigal people of the Eora Nation. We pay our respects to their Elders past and present and extend that respect to all Aboriginal and Torres Strait Islander cultures. See omnystudio.com/listener for privacy information.

What's in store for the cannabis industry in 2021? Join us as we sit down with Rhys Cohen, cannabis Industry consultant and journalist, to discuss what to expect for the cannabis industry in 2021. Rhys discusses his involvement in the industry over the past 4 years since legalisation, including his work at the famous Lambert Initiative! 

In this episode Scott and Adam chat with Dr. Thomas Arkell of the Lambert Initiative about his recently published study into the effects of CBD and THC on driving and impairment. This is a groundbreaking clinical trial which holds global ramifications for policy makers. Dr. Arkell's study has raised serious questions about roadside drug testing policy and this hour long chat is well worth a listen!

Pretty much every week, we get an email from a new cannabis startup, promoting their latest CBD or THC remedy to treat any number of health conditions, including sleep problems. This boom in new, legal cannabis products is the result of recent legislation to start the process of widespread marijuana decriminalisation, and eventually full legalisation. But whilst the consumer demand is fuelling massive growth in the global cannabis industry, currently, there's little, verging on zero clinical evidence to firmly substantiate many of the health claims made by the new wave of cannabis products hitting the market. So in this episode, we go behind the marketing claims, and look at the real, solid, scientific evidence behind medical cannabis and its efficacy in treating insomnia and a whole host of other sleep disorders including sleep apnea, restless legs syndrome, and even narcolepsy. This episode's guest:   Anastasia Suraev is a clinical research officer at the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically-funded centre for cannabinoid research at the University of Sydney. She is also a PhD candidate at the Woolcock Institute of Medical Research where she is leading a clinical trial assessing the effects of a cannabis-based therapy on sleep in people with chronic insomnia. University of Sydney: https://www.sydney.edu.au/science/about/our-people/academic-staff/anastasia-suraev.html Lambert Initiative for Cannabinoid Therapeutics: https://www.sydney.edu.au/lambert/: Systematic Review: Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies Episode Homepage: http://sleepjunkies.com/cannabis-sleep-medicine/ More Episodes:

Pretty much every week, we get an email from a new cannabis startup, promoting their latest CBD or THC remedy to treat any number of health conditions, including sleep problems. This boom in new, legal cannabis products is the result of recent legislation to start the process of widespread marijuana decriminalisation, and eventually full legalisation. But whilst the consumer demand is fuelling massive growth in the global cannabis industry, currently, there's little, verging on zero clinical evidence to firmly substantiate many of the health claims made by the new wave of cannabis products hitting the market. So in this episode, we go behind the marketing claims, and look at the real, solid, scientific evidence behind medical cannabis and its efficacy in treating insomnia and a whole host of other sleep disorders including sleep apnea, restless legs syndrome, and even narcolepsy. This episode's guest:   Anastasia Suraev is a clinical research officer at the Lambert Initiative for Cannabinoid Therapeutics, a philanthropically-funded centre for cannabinoid research at the University of Sydney. She is also a PhD candidate at the Woolcock Institute of Medical Research where she is leading a clinical trial assessing the effects of a cannabis-based therapy on sleep in people with chronic insomnia. University of Sydney: https://www.sydney.edu.au/science/about/our-people/academic-staff/anastasia-suraev.html Lambert Initiative for Cannabinoid Therapeutics: https://www.sydney.edu.au/lambert/: Systematic Review: Cannabinoid therapies in the management of sleep disorders: A systematic review of preclinical and clinical studies Episode Homepage: https://sleepjunkies.com/cannabis-sleep-medicine/ More Episodes:

SPECIAL GUEST: Samuel Banister (USyd) The cannabis plant is useful for everything from textiles to medicine, however our ability to use these plants has been hampered by its association with illegal drugs. People are beginning to make very big claims about the use of cannabinoids to treat almost every ailment under the sun, however the evidence still just isn’t there. Samuel Banister is a medicinal chemist at the Lambert Initiative at the University of Sydney that studies how drugs affect our brains and bodies in both good and bad ways. He studies how the chemicals found in cannabis might be used to treat conditions such as epilepsy and certain cancers. Support In Situ Science on Patreon Sam also studies how illicit drugs affect the brain and the chemical pathways behind their effects. In this interview with In Situ Science we chat about the benefits of voluntary pill testing, and whether the prohibition of drugs can cause more harm than good. We also talk about the challenges of understanding the effects of recreational drugs with new drugs constantly being developed and finding their way out into the streets.   Follow Sam on Twitter @samuel_b_phd or find out more about the Lambert Initiative here Follow us on Twitter @insituscience Follow us on Instagram        Like us on Facebook                                          Music: ‘Strange Stuff’ by Sonic Wallpaper - www.sonicwallpaper.bandcamp.com

More about developments in cannabinoid science as a follow on from a previous discussion about medical cannabis. Professor Iain McGregor is Academic Director of the Lambert Initiative for Cannabinoid Therapeutics which is part of the Brain and Mind Centre at the University of Sydney. As well as explaining the human endocannabinoid system and the potential medicinal uses of various components of cannabis plants, Iain comments on the current regulatory approach to medical cannabis in Australia.

People involved in medical cannabis can find themselves in a twilight zone where the law may prevent uses of cannabinoids claimed to have life-saving effects. Professor Iain McGregor explains the vision, stories and studies behind the University of Sydney’s Lambert Initiative for Cannabinoid Therapeutics. Soundbite and transcript at http://sydney.edu.au/news-opinion/news/2017/09/25/is-medical-marijuana-the-next-wonder-drug-podcast.html

With nearly one-third of people with epilepsy having forms resistant to current medication, some people turn to medical cannabis, driven by hope – and anecdotal evidence claiming – that it will work. Now, researchers at the University of Sydney’s Lambert Initiative, in partnership with Epilepsy Action Australia, are seeking out parents who use cannabis-based medicines to treat their child’s epilepsy.

With nearly one-third of people with epilepsy having forms resistant to current medication, some people turn to medical cannabis, driven by hope – and anecdotal evidence claiming – that it will work. Now researchers at the University of Sydney’s Lambert Initiative, in partnership with Epilepsy Action Australia, are seeking out parents who use cannabis-based medicines to treat their child’s epilepsy.

With nearly one-third of people with epilepsy having forms resistant to current medication, some people turn to medical cannabis, driven by hope – and anecdotal evidence claiming – that it will work. Now researchers at the University of Sydney’s Lambert Initiative, in partnership with Epilepsy Action Australia, are seeking out parents who use cannabis-based medicines to treat their child’s epilepsy.